Break it Down: One step closer to treating ALS
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
In this episode, Tylah Tully gives the skinny on Neurizon Therapeutics (ASX:NUZ) HEALEY ALS Platform Trial, as the company makes progress developing its lead asset NUZ-001.
Tune in to get the latest.
Related Topics
Related Stories
SUBSCRIBE
Get the latest breaking news and stocks straight to your inbox.
It's free. Unsubscribe whenever you want.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
